MMMichaël Maes

Michaël Maes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michaël Maes has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Nonclinical Development of Oligonucleotide-Based Therapeutics: Insights from an IQ DruSafe ONT Working Group Survey

    by Tod A. Harper Jr, Yi Yang, Sucheta Mukherjee, Marie Coeffet, Katja A. Matheis, Alan Brown, Joel D. Parry, Patrik Andersson, Onyi N. Irrechukwu, Michaël Maes, et al.

    Oligonucleotide-based therapeutics (ONTs) present unique nonclinical development challenges that are not fully addressed by paradigms established for small molecule pharmaceuticals or biologic therapeutics. To better understand current industry practice, the IQ DruSafe ONT Working Group conducted an industry survey examining species selection and high-dose selection in GLP repeat-dose toxicology studies, parameters used to determine safety margins, and human equivalent dose (HED) scaling used to support initial dose selection for first-in-human studies. Twenty companies provided responses, largely reflecting experience with systemically administered siRNA and RNase H antisense ONTs. Common themes identified in the survey included frequent use of both rodent and non-rodent species, with nonhuman primates used extensively, and high-dose selection based on an integrated consideration of maximum tolerated dose, pharmacodynamic response, and exposure-based criteria. Safety margins were most often based on steady-state exposure, generally using plasma rather than tissue exposure. For HED scaling, body surface area was the predominant approach, although some respondents reported use of body weight- or platform-informed alternatives. Overall, the survey identifies areas of convergence in current ONT nonclinical practice while highlighting unresolved areas where nonclinical practices diverge. The survey also identified areas where future ONT-specific regulatory guidance could improve consistency across ONT development programs.

  • Open Access

    An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics

    by Jennifer D Sisler, Patrik Andersson, Alan Brown, Carole Harbison, Onyi Irrechukwu, Helen Lightfoot, Michaël Maes, Sucheta Mukherjee, Joel D Parry, Justin Schumacher, et al.

    Oligonucleotide therapeutics (ONTs) are a growing class of nucleic acid–based therapies with the potential to treat a variety of diseases through several different mechanisms of action (MoA). The most prevalent MoA entails the inhibition of therapeutically relevant levels of protein expression via mRNA degradation, exemplified by numerous approved ONTs. ONTs have unique physicochemical properties, pharmacokinetic characteristics, and MoAs that are distinct from other drug classes. The result can be a disconnect between the administered dose, plasma drug concentrations, pharmacodynamics, and toxicity. Thus, ONT development poses unique scientific and regulatory challenges that are not fully addressed by current International Council for Harmonisation (ICH) guidelines. The complexity of ONT development has recently been recognized with the acceptance of the new ICH topic proposal “ICH S13—Nonclinical Safety Evaluation of Oligonucleotide-based Therapeutics.” In preparation for the ICH S13 Step 2 public consultation period, the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) DruSafe ONT Working Group convened to identify and discuss key considerations for ONT development, and to communicate areas where regulatory clarity and harmonization are most needed. Specifically, these include strategies to assess off-target toxicities, safety pharmacology, general toxicity studies, First-In-Human dose selection, genotoxicity studies, reproductive and developmental toxicity studies, carcinogenicity assessments, and the appropriate use of a surrogate molecule in development. The intended goals of this paper are to provide a means for communicating input towards the ICH process and to provide a resource for assisting with the public review of the draft ICH S13 Guidance.


  • Open Access

    TAT-Gap19 and Carbenoxolone Alleviate Liver Fibrosis in Mice

    by Sara Crespo Yanguas, Tereza C. Da Silva, Isabel V. A. Pereira, Joost Willebrords, Michaël Maes, Marina Sayuri Nogueira, Inar Alves de Castro, Isabelle Leclercq, Guilherme R. Romualdo, Luís F. Barbisan, et al.

    Although a plethora of signaling pathways are known to drive the activation of hepatic stellate cells in liver fibrosis, the involvement of connexin-based communication in this process remains elusive. Connexin43 expression is enhanced in activated hepatic stellate cells and constitutes the molecular building stone of hemichannels and gap junctions. While gap junctions support intercellular communication, and hence the maintenance of liver homeostasis, hemichannels provide a circuit for extracellular communication and are typically opened by pathological stimuli, such as oxidative stress and inflammation. The present study was set up to investigate the effects of inhibition of connexin43-based hemichannels and gap junctions on liver fibrosis in mice. Liver fibrosis was induced by administration of thioacetamide to Balb/c mice for eight weeks. Thereafter, mice were treated for two weeks with TAT-Gap19, a specific connexin43 hemichannel inhibitor, or carbenoxolone, a general hemichannel and gap junction inhibitor. Subsequently, histopathological analysis was performed and markers of hepatic damage and functionality, oxidative stress, hepatic stellate cell activation and inflammation were evaluated. Connexin43 hemichannel specificity of TAT-Gap19 was confirmed in vitro by fluorescence recovery after photobleaching analysis and the measurement of extracellular release of adenosine-5′-triphosphate. Upon administration to animals, both TAT-Gap19 and carbenoxolone lowered the degree of liver fibrosis accompanied by superoxide dismutase overactivation and reduced production of inflammatory proteins, respectively. These results support a role of connexin-based signaling in the resolution of liver fibrosis, and simultaneously demonstrate the therapeutic potential of TAT-Gap19 and carbenoxolone in the treatment of this type of chronic liver disease.


  • Protective effect of genetic deletion of pannexin1 in experimental mouse models of acute and chronic liver disease

    by Joost Willebrords, Michaël Maes, Isabel Veloso Alves Pereira, Tereza Cristina da Silva, Veronica Mollica Govoni, Valéria Veras Lopes, Sara Crespo Yanguas, Valery I. Shestopalov, Marina Sayuri Nogueira, Inar Alves de Castro, et al.


  • Inhibitors of connexin and pannexin channels as potential therapeutics

    by Joost Willebrords, Michaël Maes, Sara Crespo Yanguas, Mathieu Vinken


  • Open Access

    Inhibition of connexin hemichannels alleviates non-alcoholic steatohepatitis in mice

    by Joost Willebrords, Bruno Cogliati, Isabel Veloso Alves Pereira, Tereza Cristina da Silva, Sara Crespo Yanguas, Michaël Maes, Veronica Mollica Govoni, Andressa Lima, Daniele Aparecida Felisbino, Elke Decrock, et al.

    While gap junctions mediate intercellular communication and support liver homeostasis, connexin hemichannels are preferentially opened by pathological stimuli, including inflammation and oxidative stress. The latter are essential features of non-alcoholic steatohepatitis. In this study, it was investigated whether connexin32 and connexin43 hemichannels play a role in non-alcoholic steatohepatitis. Mice were fed a choline-deficient high-fat diet or normal diet for 8 weeks. Thereafter, TAT-Gap24 or TAT-Gap19, specific inhibitors of hemichannels composed of connexin32 and connexin43, respectively, were administered for 2 weeks. Subsequently, histopathological examination was carried out and various indicators of inflammation, liver damage and oxidative stress were tested. In addition, whole transcriptome microarray analysis of liver tissue was performed. Channel specificity of TAT-Gap24 and TAT-Gap19 was examined in vitro by fluorescence recovery after photobleaching analysis and measurement of extracellular release of adenosine triphosphate. TAT-Gap24 and TAT-Gap19 were shown to be hemichannel-specific in cultured primary hepatocytes. Diet-fed animals treated with TAT-Gap24 or TAT-Gap19 displayed decreased amounts of liver lipids and inflammatory markers, and augmented levels of superoxide dismutase, which was supported by the microarray results. These findings show the involvement of connexin32 and connexin43 hemichannels in non-alcoholic steatohepatitis and, simultaneously, suggest a role as potential drug targets in non-alcoholic steatohepatitis.


  • Connexin hemichannel inhibition reduces acetaminophen-induced liver injury in mice

    by Michaël Maes, Sara Crespo Yanguas, Joost Willebrords, James L. Weemhoff, Tereza Cristina da Silva, Elke Decrock, Margitta Lebofsky, Isabel Veloso Alves Pereira, Luc Leybaert, Anwar Farhood, et al.


  • Open Access

    Connexin-based signaling and drug-induced hepatotoxicity

    by Michaël Maes, Mathieu Vinken

    Being critical mediators of liver homeostasis, connexins and their channels are frequently involved in liver toxicity. In the current paper, specific attention is paid to actions of hepatotoxic drugs on these communi- cative structures. In a first part, an overview is provided on the structural, regulatory and functional proper ties of connexin-based channels in the liver. In the second part, documented effects of acetaminophen, hypolipidemic drugs, phenobarbital and methapyriline on connexin signaling are discussed. Furthermore, the relevance of this subject for the fields of clinical and in vitro toxicology is demonstrated. Relevance for patients: The role of connexin signaling in drug-induced hepatotoxicity may be of high clinical relevance, as it offers perspectives for the therapeutic treatment of such insults by interfering with connexin channel opening.


  • Pannexin1 as mediator of inflammation and cell death

    by Sara Crespo Yanguas, Joost Willebrords, Scott R. Johnstone, Michaël Maes, Elke Decrock, Marijke De Bock, Luc Leybaert, Bruno Cogliati, Mathieu Vinken


  • Connexin32 deficiency is associated with liver injury, inflammation and oxidative stress in experimental non‐alcoholic steatohepatitis

    by Taynã Cristina Tiburcio, Joost Willebrords, Tereza Cristina da Silva, Isabel Veloso Alves Pereira, Marina Sayuri Nogueira, Sara Crespo Yanguas, Michaël Maes, Elisangela dos Anjos Silva, Maria Lucia Zaidan Dagli, Inar Alves de Castro, et al.

    Summary: Non‐alcoholic steatohepatitis is a highly prevalent liver pathology featured by hepatocellular fat deposition and inflammation. Connexin32, which is the major building block of hepatocellular gap junctions, has a protective role in hepatocarcinogenesis and is downregulated in chronic liver diseases. However, the role of connexin32 in non‐alcoholic steatohepatitis remains unclear. Connexin32−/− mice and their wild‐type littermates were fed a choline‐deficient high‐fat diet. The manifestation of non‐alcoholic steatohepatitis was evaluated based on a battery of clinically relevant read‐outs, including histopathological examination, diverse indicators of inflammation and liver damage, in‐depth lipid analysis, assessment of oxidative stress, insulin and glucose tolerance, liver regeneration and lipid‐related biomarkers. Overall, more pronounced liver damage, inflammation and oxidative stress were observed in connexin32−/− mice compared to wild‐type animals. No differences were found in insulin and glucose tolerance measurements and liver regeneration. However, two lipid‐related genes, srebf1 and fabp3, were upregulated in Cx32−/− mice in comparison with wild‐type animals. These findings suggest that connexin32‐based signalling is not directly involved in steatosis as such, but rather in the sequelae of this process, which underlie progression of non‐alcoholic steatohepatitis.